Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Does detection of K-ras mutations in pancreatic juice influence clinical decision making?
Autore:
OMahony, S; Sreedharan, A;
Indirizzi:
Gen Infirm Leeds, Gastroenterol Unit, Leeds LS1 3EX, W Yorkshire, England Gen Infirm Leeds Leeds W Yorkshire England LS1 3EX , W Yorkshire, England
Titolo Testata:
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
fascicolo: 10, volume: 13, anno: 2001,
pagine: 1141 - 1142
SICI:
0954-691X(200110)13:10<1141:DDOKMI>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
POINT MUTATIONS; DIAGNOSIS; CODON-12; GENE; CARCINOMA; ONCOGENE; BILIARY; CANCER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
12
Recensione:
Indirizzi per estratti:
Indirizzo: O'Mahony, S Gen Infirm Leeds, Gastroenterol Unit, Great George St, Leeds LS1 3EX, W Yorkshire, England Gen Infirm Leeds Great George St Leeds W Yorkshire England LS1 3EX
Citazione:
S. O'Mahony e A. Sreedharan, "Does detection of K-ras mutations in pancreatic juice influence clinical decision making?", EUR J GASTR, 13(10), 2001, pp. 1141-1142

Abstract

The majority of patients with pancreatic cancer harbour mutations in the K-ras gene. This oncogene may be detected in material obtained at endoscopicretrograde cholangiopancreatography (ERCP), such as bile and pancreatic juice. Since a formal tissue diagnosis may be difficult to establish in pancreatic cancer, detection of Kras in these materials is an attractive approach to diagnosis. A variety of molecular techniques has been used to detect K-ras, and frequency of the mutation may vary between different populations. In this issue of the European Journal of Gastroenterology and Hepatology, Boadas et al. collected pancreatic juice following secretin stimulation at the time of ERCP, and detected K-ras in 44% of patients with pancreatic cancer. They found the mutation in 16% of patients with chronic pancreatitis. Presence of the mutation, therefore, is not specific enough to recommend its use in the clinical diagnosis of pancreatic cancer. Chronic pancreatitis patients with the mutation may be at higher risk of developing pancreatic cancer than those patients without the mutation, but there is no clear consensus on management and follow-up of these patients. Eur J Gastroenterol Hepatol 13:1141-1142 (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/01/20 alle ore 07:04:32